CIK 0001817241 · <br>Emerging growth company
Artiva Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARTV
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863614316
- Phone
- (858) 267-4467
- Business address
- 5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,341,159
- in 16 filings, $529K under 10b5-1 plans
Net −$2,341,159. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-26 | Horan Christopher Chief Tech Operations Officer | Grant or award | +60,000 | 85,000 | ||
| 2025-02-26 | Krishnamohan Neha Chief Financial Officer | Grant or award | +60,000 | 110,000 | ||
| 2025-02-26 | Bush Jennifer COO, CLO, Secy, Compliance Off | Grant or award | +86,650 | 159,449 | ||
| 2025-01-28 | Baker Daniel G. Director | Grant or award · Director Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2024-10-21 | MOORE ALISON Director | Grant or award · Director Stock Option (Right to Buy) | +27,500 | 27,500 | ||
| 2024-09-12 | Raymon Heather SVP, Research and Development | Grant or award | +10,000 | 10,000 | ||
| 2024-09-12 | Graef Thorsten Chief Medical Officer | Grant or award | +20,000 | 20,000 | ||
| 2024-09-12 | Horan Christopher Chief Tech Operations Officer | Grant or award | +25,000 | 25,000 | ||
| 2024-09-12 | Krishnamohan Neha Chief Financial Officer | Grant or award | +50,000 | 50,000 | ||
| 2024-09-12 | Bush Jennifer COO, CLO, Secy, Compliance Off | Grant or award | +50,000 | 72,799 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +725,391 | 725,391 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +264,571 | 264,571 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +68,320 | 68,320 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Other acquisition | +323,181 | $10.20 | $3.3M | 1,048,572 |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Other acquisition | +138,506 | $10.20 | $1.4M | 138,506 |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +7,645,007 | $12.00 | $91.7M | 8,693,579 |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +688,326 | $12.00 | $8.3M | 826,832 |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −564,372 | 0 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −210,898 | 0 | ||
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −68,320 | 0 |
Page 8 of 11 · 203 trades